{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:15Z","timestamp":1790969715891,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>\n                           <jats:italic>Summary<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>Persistence with initial treatment was highest after 1\u00a0year, decreasing afterwards. Persistence was highest for denosumab followed by alendronate. We identified several factors associated with treatment persistence, some of which were the same irrespective of OTx agent, which could help target subgroups of patients in terms of social and healthcare support.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To describe patient characteristics, persistence, and factors associated with the persistence of new users of the bisphosphonates (alendronate, risedronate, and ibandronate) and the RANKL inhibitor denosumab in Denmark.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A population-based cohort study using health registries (2010\u20132018). We included alendronate (<jats:italic>n<\/jats:italic>\u2009=\u2009128,590), risedronate (<jats:italic>n<\/jats:italic>\u2009=\u2009892), ibandronate (<jats:italic>n<\/jats:italic>\u2009=\u20095,855), and denosumab (<jats:italic>n<\/jats:italic>\u2009=\u200916,469) users, aged\u2009\u2265\u200950\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The 1-year persistence was 68.2% in the alendronate cohort; 39.3% in the risedronate cohort; 56.3% in the ibandronate cohort; and 84.0% in the denosumab cohort. The 2-year persistence was 58.7% in the alendronate cohort; 28.0% in the risedronate cohort; 42.9% in the ibandronate cohort; and 71.9% in the denosumab cohort. The 4-year persistence was 46.3%, 15.4%, 29.6%, and 56.9%, respectively. Later years of treatment initiation were associated with lower persistence for alendronate (adjusted odds ratio (OR) with 95% CI was 0.86 (0.81\u20130.91) in 2016 compared to 2010), but not for risedronate (OR was 1.56 (0.60\u20134.06), ibandronate (OR was 0.92 (0.71\u20131.19) or denosumab (OR was 1.11 (0.87\u20131.43). Older age was associated with higher persistence for all medications and the same goes for the female sex except for ibandronate. Dementia was associated with higher persistence for alendronate but not denosumab, whereas prior osteoporosis treatment (OT) was the opposite. Several comorbidities were associated with lower persistence for alendronate, but not denosumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Persistence was highest for denosumab followed by alendronate. We identified several factors associated with treatment persistence, some of which were the same irrespective of OTx agent, which could help target subgroups of patients in terms of social and healthcare support.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-023-01210-4","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:02:55Z","timestamp":1673438575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-9401","authenticated-orcid":false,"given":"Alma B.","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolaj","family":"Risbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kafatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neasham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"O\u2019Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-3254","authenticated-orcid":false,"given":"Vera","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"issue":"1\u20132","key":"1210_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1\u20132):136","journal-title":"Arch Osteoporos"},{"key":"1210_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.bone.2018.12.016","volume":"120","author":"B Abrahamsen","year":"2019","unstructured":"Abrahamsen B, Skjodt MK, Vestergaard P (2019) Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention. Bone 120:476\u2013481","journal-title":"Bone"},{"key":"1210_CR3","unstructured":"Selskab DK (2009) Vejledning til udredning og behandling af osteoporose. https:\/\/www.endocrinology.dk. Accessed 10\/01 2023"},{"key":"1210_CR4","unstructured":"EMA. Prolia (denosumab) [Available from:\u00a0http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001120\/human_med_001324.jsp&mid=WC0b01ac058001d124. Accessed 10\/01 2023"},{"issue":"9","key":"1210_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00198-019-05066-8","volume":"30","author":"PK Kristensen","year":"2019","unstructured":"Kristensen PK, Ehrenstein V, Shetty N, Pedersen AB (2019) Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better? Osteoporos Int 30(9):1817\u20131825","journal-title":"Osteoporos Int"},{"issue":"3","key":"1210_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-016-3789-y","volume":"28","author":"M Belhassen","year":"2017","unstructured":"Belhassen M, Confavreux CB, Cortet B, Lamezec L, Ginoux M, Van Ganse E (2017) Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int 28(3):853\u2013862","journal-title":"Osteoporos Int"},{"issue":"1","key":"1210_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1210_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jep.12422","volume":"22","author":"S Ferguson","year":"2016","unstructured":"Ferguson S, Feudjo Tepie M, Taylor A, Roddam A, Critchlow C, Iqbal M et al (2016) The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink. J Eval Clin Pract 22(1):31\u201339","journal-title":"J Eval Clin Pract"},{"issue":"10","key":"1210_CR9","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27(10):2967\u20132978","journal-title":"Osteoporos Int"},{"issue":"7","key":"1210_CR10","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00198-012-2221-5","volume":"24","author":"C Hansen","year":"2013","unstructured":"Hansen C, Pedersen BD, Konradsen H, Abrahamsen B (2013) Anti-osteoporotic therapy in Denmark\u2013predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int 24(7):2079\u20132097","journal-title":"Osteoporos Int"},{"issue":"10","key":"1210_CR11","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401\u20132411","journal-title":"Osteoporos Int"},{"issue":"10","key":"1210_CR12","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s00198-017-4144-7","volume":"28","author":"C Reyes","year":"2017","unstructured":"Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C et al (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 28(10):2997\u20133004","journal-title":"Osteoporos Int"},{"issue":"2","key":"1210_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures\u2013the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433\u2013443","journal-title":"Osteoporos Int"},{"issue":"4","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049","journal-title":"BMJ Open"},{"key":"1210_CR15","first-page":"100678","volume":"13","author":"AS Solling","year":"2021","unstructured":"Solling AS, Christensen DH, Darvalics B, Harslof T, Thomsen RW, Langdahl B (2021) Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. Osteoporos Int 13:100678","journal-title":"Osteoporos Int"},{"issue":"5","key":"1210_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00391-019-01559-7","volume":"52","author":"M Gosch","year":"2019","unstructured":"Gosch M, Kammerlander C, Neuerburg C (2019) Osteoporosis-epidemiology and quality of care. Z Gerontol Geriatr 52(5):408\u2013413","journal-title":"Z Gerontol Geriatr"},{"issue":"8","key":"1210_CR17","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00198-018-4560-3","volume":"29","author":"M Hoff","year":"2018","unstructured":"Hoff M, Skurtveit S, Meyer HE, Langhammer A, Sogaard AJ, Syversen U et al (2018) Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study. Norway Osteoporos Int 29(8):1875\u20131885","journal-title":"Norway Osteoporos Int"},{"issue":"1","key":"1210_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 8(1):136","journal-title":"Arch Osteoporos."},{"key":"1210_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563\u2013591","journal-title":"Clin Epidemiol"},{"issue":"3","key":"1210_CR20","first-page":"798-f","volume":"46","author":"A Pottegard","year":"2017","unstructured":"Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M (2017) Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol 46(3):798-f","journal-title":"Int J Epidemiol"},{"issue":"7 Suppl","key":"1210_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39(7 Suppl):38\u201341","journal-title":"Scand J Public Health"},{"issue":"8","key":"1210_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, Sorensen HT (2014) The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 29(8):541\u2013549","journal-title":"Eur J Epidemiol"},{"issue":"7 Suppl","key":"1210_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl):22\u201325","journal-title":"Scand J Public Health"},{"key":"1210_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490","journal-title":"Clin Epidemiol"},{"issue":"7 Suppl","key":"1210_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1403494811408483","volume":"39","author":"F Petersson","year":"2011","unstructured":"Petersson F, Baadsgaard M, Thygesen LC (2011) Danish registers on personal labour market affiliation. Scand J Public Health 39(7 Suppl):95\u201398","journal-title":"Scand J Public Health"},{"key":"1210_CR26","unstructured":"EMA. Prolia. Summary of product characteristics 2019\u00a0[Available from:\u00a0Prolia, INN-denosumab (europa.eu).\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prolia. Accessed 10\/01 2023"},{"issue":"5","key":"1210_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"1210_CR28","unstructured":"Agency TEM (2015) Aclasta. EPAR summary for the public. https:\/\/www.ema.europa.eu. Accessed 10\/012023\u00a0"},{"issue":"7","key":"1210_CR29","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1359\/jbmr.090209","volume":"24","author":"EF Eriksen","year":"2009","unstructured":"Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD et al (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308\u20131313","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1210_CR30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00198-019-05228-8","volume":"31","author":"J Morley","year":"2020","unstructured":"Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L et al (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31(3):533\u2013545","journal-title":"Osteoporos Int"},{"issue":"1","key":"1210_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317\u2013326","journal-title":"Osteoporos Int"},{"issue":"6","key":"1210_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-014-1677-y","volume":"70","author":"A Pottegard","year":"2014","unstructured":"Pottegard A, Christensen R, Houji A, Christiansen CB, Paulsen MS, Thomsen JL et al (2014) Primary non-adherence in general practice: a Danish register study. Eur J Clin Pharmacol 70(6):757\u2013763","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1210_CR33","first-page":"e50","volume":"23","author":"RJ Romanelli","year":"2017","unstructured":"Romanelli RJ, Shah SN, Ikeda L, Lynch B, Craig TL, Cappelleri JC et al (2017) Patient characteristics and healthcare utilization of a chronic pain population within an integrated healthcare system. Am J Manag Care 23(2):e50\u2013e56","journal-title":"Am J Manag Care"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-023-01210-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01210-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:23:46Z","timestamp":1704374626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-023-01210-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s11657-023-01210-4","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reported to the Danish Data Protection Agency through registration at Aarhus University (record number: AU-2016\u2013051-000001, sequential number 880).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Alma Becic Pedersen, Nikolaj Risbo, and Vera Ehrenstein do not have any conflict of interest. The Department of Clinical Epidemiology at Aarhus University Hospital is involved in studies with funding from various pharmaceutical companies as institutional research grants. One such study, specifically an ongoing regulator-mandated postauthorization safety study of denosumab among women with postmenopausal osteoporosis, funded by Amgen Inc. through institutional funding to Aarhus University, is related to and has overlapping populations with the present study. George Kafatos, David Neasham, and James O'Kelly are employees and stockholders of Amgen Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"19"}}